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To all the women in my world, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Education is aimed at helping students get to the point where they can think on their own 
- Noam Chomsky 
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Prostate cancer (PCa) is the second most common cancer in men in the world and the fourth 
most common occurring cancer overall. However, because the harms from testing with 
prostate-specific antigen (PSA) are considered to outweigh the benefits, no governmental 
body has yet adopted a PSA-based screening program. Risk-based screening could potentially 
help reduce the proportion of men undergoing biopsy by identifying individuals at the highest 
risk of developing PCa, and thus reduce the harms of overdiagnosis and overtreatment. 
However, little is known about the psycho-social aspects surrounding risk-stratified PCa 
testing. 
This thesis, and the papers encompassed, aims to increase knowledge regarding men’s views 
on participation to individualized prostate cancer testing (PCT). Their interest in partaking in 
a risk-based PCT as well as its effect on their psycho-social health were investigated. A better 
understanding of their views, as well as predictors of participation and aspects of invitation 
would help inform development of population-based PCa screening programs to optimize 
attendance. 
By using a cross-sectional survey in Paper I, the objective was to explore the general 
population’s interest in, and acceptability of, the prospect of risk-stratified cancer screening 
programs. A representative sample of 10.000 individuals (20-74 years of age) were invited to 
respond to a web-survey with questions developed by a panel of experts. Men were asked 
about PCa screening and women were asked about breast cancer screening. 
Out of our 2822 respondents (28%), a vast majority (94%) showed interest in wanting to 
know their cancer risk, with men presenting more certainty than women. A total of 87% 
agreed to the concept that if identified with a high risk, they would get screened more often. 
Only 27%, however, would agree to get screened less often if identified as having a low risk. 
Paper II, Paper III and Paper IV studied actual participation in risk-based PCT. The PCa 
test was conducted within the frame of the STHLM3 trial, a large study for men 50-69 years 
of age in the region of Stockholm (Sweden). STHLM3 aimed at validating a risk-based PCT 
model in order to identify high-risk PCa. By participating in STHLM3, men were 
communicated their PCa risk (low, intermediate or high).  
The study sample in Paper II represented a sub-sample of 28.134 men invited to the pilot 
study of STHLM3. They were randomly allocated to different survey design factors in order 
to investigate optimization of participation rates. The study sample for Paper III and IV was 
also nested in STHLM3 and consisted of 10.000 men. They were invited to respond to a web-
survey concerning worry, knowledge, health behavior and attitudes, as well as health related 
quality of life, three months before STHLM3, at invitation to STHLM3, and five months after 
participation in STHLM3.  
Paper II and Paper III investigated predictors of participation to the risk-based PCa 
screening program. Paper II investigated survey and invitation design predictors (the use of a 
pre-notification, the length of the invitation letter, the length of the questionnaire and the use 
of a reminder or not). Paper III examined psycho-social predictors (worry, knowledge, 
health behavior and attitudes, and health-related quality of life) for participation in PCT.  
The participation rate in Paper II was 34%. The use of a pre-notification and a reminder 
increased participation to STHLM3. In Paper III, 1915 men responded to the questionnaire 
three months before invitation to STHLM3. When comparing decliners of STHLM3 (30%) 
with participants to STHLM3 (70%), participants presented more worry and an increased 
level of vulnerability, as well as a better general health than decliners.  
Finally, almost 1000 men responded to the psycho-social questionnaire three months before 
STHLM3 as well as five months after STHLM3, enabling examination of the impact over 
time of participating to the risk-based PCT in STHLM3. Men assigned to a low or 
intermediate risk level reported that the levels of worry decreased over time, whereas men 
assigned to a high-risk level reported no increased level of worry. A low level of PCa 
knowledge was observed throughout Paper III and IV, calling for improved effort on that 
front before introducing PCa screening.   
Although participation rates could still be optimized, if implemented risk-stratified screening 
has the possibility to be accepted by the general public. Moreover, the study revealed no 
negative impact on the well-being of men participating in risk-based PCa testing.  
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In 2008, a 10-year Linnaeus grant, financed by the Swedish Research Council, enabled the 
development of a Centre of Excellence at Karolinska Institutet focusing on Cancer Risk 
Prevention. The Cancer Risk Prediction Center (CRiSP) was born on a shared vision to 
decrease the mortality of breast and prostate cancer by focusing on individualized cancer risk 
prediction and prevention. Compared to traditional project funding targeting a single 
principal investigator for a few years at most, the 10-year duration of the Linnaeus grant as 
well as the size of the funding allowed researchers to think bigger. CRiSP’s steering 
committee consisted of 11 professors from Karolinska Institutet and the Karolinska 
University Hospital, from both pre-clinical and clinical departments, covering together a vast 
array of scientific fields. The long-term strategy to reach their vision was based on building 
the largest and best-characterized cancer cohorts in the world (1, 2).  
 
Through a lucky chain of events, I was introduced to Yvonne Brandberg in 2010. Yvonne is 
by profession a clinical psychologist as well as a professor in Care Science with a focus on 
Oncology. She was one of the 11 professors on CRiSP’s steering committee and I 
immediately fell in love in her projects touching upon psycho-social aspects of individualized 
cancer screening. It felt like it was marrying perfectly my biomedical background with my 
nursing training.  
 
This thesis is compiled of three published papers and a manuscript all centered around 
individualized prostate cancer testing (PCT) and men’s views on participation to PCT. I 
believe it is important to keep in mind that as a society, our assumptions and pre-conceived 
notions constantly evolve and what might have seemed an ambiguous notion years ago might 
sound like an obvious concept today. The idea of personalizing medicine has come a long 
way in ten years and has progressed from mere discussion to a self-evident concept. The 
views and opinions stated by our participants and measured in our studies are reflections of 
the society’s progress in the matter at that moment in time. When moving from a “One-size-
fits-all” screening regimen to prevention involving knowing one’s cancer risk it is important 
to keep the recipients in mind. CRiSP’s efforts would have been worthless if the recipients in 
the end did not want to know or could not cope with their cancer risk. Therefore, it was 
important to ask the general population how they felt about possibly knowing their cancer 
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risk likelihood (at the fear of possibly discovering that they did not want to know it!) as well 
as to attempt to measure the impact of individualized PCT on several psycho-social aspects. 
In simpler term, one could say that we performed a market analysis of risk-based PCT. 
 
Alaska, 2020-07-22 
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The prostate is an exocrine gland in men below the urinary bladder and located in the upper 
part of the urethra. The word prostate comes from latin prostata; pro- “before” and -sta “to 
stand” due to its position at the base of the bladder (3). Its function is to produce a thin 
secretion which contributes to the volume of the semen at ejaculation. The alkalinity of the 
prostatic fluid prolongs the lifespan of sperms by neutralizing the acidity of the vaginal tract. 
Dihydrotestosterone, a metabolite of testosterone, predominantly regulates the prostate. Many 
studies have shown a pattern of prostatic growth with age (4, 5). However, changes in 
prostate size are highly variable among aging men (6). Disorders of the prostate include 
prostate cancer, benign prostatic hyperplasia (enlarged prostate), and prostatitis 
(inflammation). 
  
In Sweden, prostate cancer (PCa) is the most common cancer and represent 16,3% of the total 
number of diagnosed cancer cases (7). Approximately a third (31,2%) of all cancers in men 
are prostate cancer. In 2016, 10.474 men were diagnosed. Median age at diagnosis is 70 
years. One out of eight men is at risk of developing prostate cancer before the age of 75 (7). 
The median age of death from PCa is 80 years. Two-thirds of all men who die of PCa are 
older than 75 years (8). Prostate cancer is found at obduction or during bladder cancer 
surgery in men without known previous PCa diagnosis in approximately a third of men in 
their 60’s, and in half of the men in their 80’s (9, 10). Autopsy studies of men who died of 
other causes have revealed that more than 20% of men aged 50-59 years and more than 33% 
of men aged 70-79 years had prostate cancer (11). Thus, not all men with prostate cancer 
experience symptoms. PCa screening is therefore important. More on this later in chapter 2.2.  
 
The actual cause of PCa is still unknown, but some risk factors have been identified. First and 
foremost, PCa incidence is strongly related to age. PCa is very uncommon in men younger 
than 45, but becomes more frequent with increasing age (12). Although an environmental 
influence on the development of PCa is presumed, an important part is played by genetic 
predisposition. Men who have a first-degree relative with PCa have twice the risk of 
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developing PCa. Moreover, men with two first-degree relatives with PCa have a five-fold 
greater risk compared to men with no family history (13). Twin studies in Scandinavia 
suggest that 42 percent of the risk may be explained by heritable factors (14). Moreover, 
differences in PCa incidence and mortality between white and Afro-american men (156 resp. 
25 in white vs. 248 resp. 59 in Afro-american men/100.000 men) (15) points to this genetic 
aspect. Although the incidence appears to be lower among Chinese and Japanese men, 
Japanese men who have migrated to the US have a higher incidence compared to men still 
living in Japan (16), reinforcing the idea that the environment play an important role. 
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In the region of Stockholm (17), the following symptoms are indications for suspicion of PCa 
and should give rise to further investigation in form of a prostate-specific antigen (PSA) test 
and prostate palpation: 
- Rapidly increasing urinary disorders (last six months) 
- Increasing skeletal pain 
- Skeletal metastases without known primary tumor 
- General cancer symptoms such as fatigue and loss of appetite. 
A referral to a urologist for investigation of PCa should be sent if: 
- Men < 70y:  PSA ≥ 3 ng/mL 
- Men 70-80y:  PSA ≥ 5 ng/mL 
- Men > 80y:  PSA ≥ 7 ng/mL 
- And/or: suspicion of malignancy at prostate palpation. 
Asymptomatic men who asks for a PSA test should be offered The National Board of Health 
and Welfare’s brochure about pro and cons regarding PSA-testing. Men with less than 15 
years of life expectancy should be dissuaded from PSA-testing. Men with more than 15 years 
of remaining life expectancy (note: average mortality in men in Sweden is 87 years) who 
want prostate cancer testing (PCT) can be offered PSA-tests according to the following 
recommended test intervals: 
- If under 65 years and PSA < 1ng/mL, test every 6 years 
- If over 65 and PSA < 1ng/mL, discontinue testing 
- If PSA 1-2,9 ng/mL, test every 2 years until they reach 75 years 
  5 
- If an increase of > 1ng/mL since last test, take a new test after one year 
- Men with low testosterone (<8mmol/L) should be tested every 2 years 
 
And finally, if belonging to a hereditary risk group (i.e. men with two or more family 
members with PCa before 75 years or known mutation in gene BRCA2 or HOXB13), a 
referral should be sent when PSA ≥ 2ng/mL. 
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The use of prostate-specific antigen (PSA) test, digital rectal examination (DRE) and core 
biopsy is the recommended way to diagnose PCa in Sweden (18). 
2.1.3.1 Prostate-specific antigen test 
PSA is a protein made by cells in the prostate gland and is mostly found in semen, but a small 
amount can also be detected in blood. A number of conditions can cause an elevation in PSA 
levels but the three most frequent ones are prostate cancer, prostatitis (inflammation) and 
benign prostatic hyperplasia (enlarged prostate). All of those conditions of the prostate can 
interfere with the natural barrier of cells between the intraductal prostatic fluid and capillaries 
and thus worsen PSA leakage into blood causing an elevated PSA level. Moreover, PSA 
levels also tend to increase with age. It is believed this is due to a deterioration over time of 
the glandular structure, facilitating PSA to leak into capillaries. That is why PSA values are 
difficult to interpret. PSA levels may vary over time in the same man and there is no specific 
normal or abnormal level of PSA in the blood. Most men without PCa have PSA levels under 
4 ng/mL of serum. Men with a PSA level between 4 and 10 have a 1 in 4 risk of having PCa. 
If the PSA is above 10, the risk of having PCa is over 50%. But some men with PSA levels 
below 4.0 ng/mL have PCa and some men with higher levels do not have PCa (19) 
Some tumors grow so slowly that they are unlikely to lead to death. When those tumors, that 
are not life-threatening, are detected it is called “over-diagnosis” and thus treating these 
tumors is called “over-treatment”. About 25% of men who have a prostate biopsy due to an 
elevated PSA level are found to have PCa following a biopsy. (20) 
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While it is normal for men to have some PSA in their blood, a raised level can be a sign of 
PCa. But PSA can be raised for many other reasons too, leading to an abnormal PSA result 
despite no presence of cancer (false-positive result). As mentioned earlier, inflammation 
and/or enlargement of the prostate can cause elevated PSA. A urinary infection can cause 
very high PSA-levels. It can take up to a year for the value to drop back to normal levels. 
Acute urinary retention also increases PSA-levels. And finally, because PSA production is 
dependent on testosterone, men with hypogonadism (diminished functional activity of the 
gonads) can have an advanced PCa despite low PSA-values.  
 
Other aspects that can affect the PSA-value are sample management for example. The way 
the blood sample is handled can affect the PSA value. For example, the ratio of free/total 
PSA decreases if the sample is being left for more than 3 hours without being centrifuged or 
cooled. Moreover, there is a variation of approximately 5% between different laboratories in 
Sweden.  
Figure 1. The PSA test 
 
Credit: Cancer Research UK 
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2.1.3.2 Digital rectal examination 
A digital rectal examination (DRE) is an internal examination of the rectum to, in the case of 
PCa suspicion, palpate the surface of the prostate gland to assess its texture, shape, size and 
tenderness. Although being simple and complication-free, it is subjective since it is dependent 
on the examiner (21). Although commonly used to screen for PCa, its benefits have been 
disputed (22). The US Preventive Task Force do not recommend DRE as a first-line method 
of PCa screening due to the lack of evidence supporting its efficacy (23). In Sweden, DRE is 
still performed (18) 
 
2.1.3.3 Prostate biopsy 
When PCa is suspected, a prostate biopsy is performed. The clinical judgment to proceed 
with a prostate biopsy depends on risk factors such as age, PSA-levels, DRE findings, a 
positive family history of PCa, previous prostate biopsy, and the patient’s life expectancy 
(24). However, diagnosing PCa cannot be performed without a biopsy and is based on the 
microscopic assessment of prostate tissue obtained via needle biopsy. A biopsy can be 
performed transperineally or transrectally. The most common method is transrectal 
ultrasound-guided (TRUS) biopsy. In a systematic fashion, 10-14 cores are taken from 
different regions of the prostate gland in a grid-like pattern. Although systematic, it is a 
method that misses a quarter of PCa (25). Since approximately 2005, multi-parametric 
magnetic resonance imaging (mpMRI) has been used to better identify and characterize 
prostate cancer (26). Prostate cancers missed by conventional biopsy are detectable by MRI-
guided targeted biopsy (27). Indications for targeted biopsy include for example patients for 
whom traditional TRUS biopsies have been negative despite concern for rising PSA (28). 
 
One of the most frequent complication of prostate biopsies is bleeding (hematuria, 
hematospermia, rectal bleeding) (29) and varies with factors such as prostate size, 
anticoagulative medication, and number of biopsy cores taken (30). Approximately, 3% of 
cases require hospitalization due to infectious complications (bacteriuria, urinary tract 
infection, epididymitis, meningitis, sepsis) (31). Prostate biopsy is also associated with 
significant pain, discomfort, and anxiety (32). Those side-effects represent the physical harms 
when screening for PCa and are the reasons why unnecessary biopsies should be avoided.  
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2.1.3.4 Grading and staging of prostate cancer 
In order to choose the most appropriate type of treatment, the cancer will be staged and 
graded. Staging is to determine its size and eventual spread to other parts of the body whereas 
grading describes the cancer cells. The most commonly used staging system is the TNM 
classification. TNM stands for Tumor, Nodes and Metastasis and aims at describing the size 
of the tumor, its spread to lymph nodes and the existence of metastases.  
 
For many years, the Gleason scoring system has been used by pathologists for grading the 
biopsy samples and issues a primary Gleason grade for the predominant histological pattern 
and a secondary grade for the highest pattern. They are both based on the microscopic 
architecture and appearance of the cells and represent a scale of 1 to 5 and are being added to 
each other to get a Gleason score sum. In 2014, a consensus conference revised pathological 
grading into 5 strata called the International Society of Urological Pathology (ISUP) score 
(33, 34). This new grading system was incorporated into the 2016 World Health Organization 
classification of tumors, and has gradually been introduced since then.  
 
For men diagnosed with localized PCa, clinicians stratify the diagnosis in low, intermediate 
and high risk of progression to determine the most appropriate course of treatment. The risk 
is determined by combining biopsy grading, clinical staging and pre-biopsy PSA levels  
In Sweden, the risk groups are defined as follow (18):   
- Low risk cancer: T1-T2a, Gleason score sum ≤ 6 and PSA < 10ng/mL 
- Middle risk cancer: T2b and/or Gleason score of 7 and/or PSA 10-19.9ng/mL 
- High risk cancer: T3-4 and/or N1 and/or M1 and/or Gleason score sum 8-10 and/or 
PSA ≥ 20 ng/mL 
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Figure 2. Risk prognosis in relation to ISUP grading score and Gleason score 
 
Credit: Prostate Cancer Foundation (pcf.org) 
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For men diagnosed with PCa, several management options exist. The precision in identifying 
and characterizing PCa tumors has increased over time and allows clinicians to stratify 
patients by risk and to recommend therapy based on patient preference and cancer prognosis. 
The treatment course depends on the cancer risk stage.  
 
For men with low-risk PCa, active surveillance has become the recommended approach (35) 
because those cancers are expected to grow slowly. Active surveillance (or active monitoring) 
tries to avoid or delay unnecessary treatment by monitoring the disease progression. It 
requires regular monitoring and curative treatment is offered if/when the cancer gets worse 
over time. Active monitoring has its pros and cons. By undergoing active monitoring, patients 
can potentially avoid eventual side-effects of curative treatment methods (such as erectile, 
rectal and urinary dysfunction) but may suffer from psychological aspects from living with 
untreated cancer and the fear of disease progression (36). A UK-based study, The Prostate 
testing for cancer and Treatment (ProtecT) trial, showed that active monitoring is as effective 
as surgery and radiotherapy in terms of survival at 10 years (37). Moreover, the same trial 
showed no differences between the different treatment groups (active monitoring, 
radiotherapy, and surgery) in terms of anxiety, depression and health-related quality of life 
(38). Moreover, a systematic review performed in 2014 concluded that men on active 
surveillance report good levels of well-being and do not suffer major negative psychological 
impacts (39).  
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Men diagnosed with localized disease (no lymph nodes or distant metastases) and with a PSA 
> 10 ng/mL and palpable nodule during DRE are offered surgery and/or radiation. PCa 
treatment side effects include, among others, erectile dysfunction, urinary issues, 
incontinence, and can diminish men’s quality of life. Finally, the first-line treatment for 
metastatic PCa continues to be androgen deprivation therapy (ADT).  
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The World Health Organization (WHO) defines screening as a process that begins with 
invitation to participate and ends with treatment for appropriately identified individuals. The 
practice of screening is an important mode of cancer prevention and early detection. The 
objective of early detection and prevention of cancer is to decrease, reverse or eliminate one’s 
risk of developing and dying of cancer (40). Primary prevention mechanisms (e.g., increased 
physical activity, changes in diet, tobacco cessation, use of sunscreen, etc.) can reduce the 
impact of exposures to factors that could induce cancer. Secondary prevention strategies, 
such as cancer screening, allow for the early detection of precancerous lesions or help inhibit, 
or even reverse, cancer progression. Tertiary prevention methods are used to help keep a 
localized cancer from spreading or metastasizing (40). Recent advances in the field of cancer 
have pushed cancer prevention to incorporate molecular knowledge and risk stratification 
profiles to allow screening regimens to be matched to one’s risk of cancer (40). 
 
In 1968, the WHO commissioned a report from Wilson and Jungner asking them to define 
screening criteria in order to guide the selection of conditions that would be suitable for 
screening (41) (see Box 1). Due to advances in genetic screening, those screening criteria 
were revised in 2008 (42) (see Box 2).  
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This thesis will add knowledge relating to several criteria needed to be met for prostate 
cancer screening to become an organized screening program. As Wilson and Jungner 
mention in their report, the test should be “acceptable to the population”. This will be 
discussed further on. Moreover, as suggested by Andermann et al. the screening program 
should “integrate education” and “ensure informed choice”. Those aspects will also be 
discussed in this thesis.  
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In November 2018, the Swedish National Board of Health and Welfare (Socialstyrelsen) 
decided that PCa screening with PSA-test should not be offered to men in the 50-70 years of 
age range (43). The same year, the U.S. Preventive Services Task Force (USPSTF) made a 
similar conclusion and decided to recommend against PSA-based screening for PCa in men 
70 years and older; and for men aged 55 to 69 years, the decisions to undergo PCa screening 
with PSA test should be made on an individual level (23). The main reason behind those 
Box 1. Wilson and Jungner classic screening criteria 
 
1. The condition sought should be an important health problem. 
2. There should be an accepted treatment for patients with recognized disease. 
3. Facilities for diagnosis and treatment should be available. 
4. There should be a recognizable latent or early symptomatic stage. 
5. There should be a suitable test or examination. 
6. The test should be acceptable to the population. 
7. The natural history of the condition, including development from latent to declared disease, should 
be adequately understood. 
8. There should be an agreed policy on whom to treat as patients. 
9. The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be 
economically balanced in relation to possible expenditure on medical care as a whole. 
10. Case-finding should be a continuing process and not a “once and for all” project. 
Box 2. Synthesis of emerging screening criteria proposed over the past 40 years  
• The screening programme should respond to a recognized need. 
• The objectives of screening should be defined at the outset. 
• There should be a defined target population. 
• There should be scientific evidence of screening programme effectiveness. 
• The programme should integrate education, testing, clinical services and programme management. 
• There should be quality assurance, with mechanisms to minimize potential risks of screening. 
• The programme should ensure informed choice, confidentiality and respect for autonomy. 
• The programme should promote equity and access to screening for the entire target population. 
• Programme evaluation should be planned from the outset. 
• The overall benefits of screening should outweigh the harm. 
Reprinted from Bulletin of the World Health Organization, 86 (4). Andermann, A., Blancquaert, I., Beauchamp, 
S., & Déry, V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 
years, pp 317–319. Copyright (2008). 
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decisions is that the harms associated with PSA screening outweigh the benefits. Up to now it 
has been difficult to distinguish indolent PCa from potentially fatal PCa without recourse to 
invasive detection methods. When these slow-growing harmless cancers are found, they are 
said to be ‘overdiagnosed’. A Cochrane review (44) came to the conclusion that prostate-
cancer screening with PSA did not significantly decrease PCa specific mortality. 
 
Figure 3. Prostate screening in men 
 
Credit: Cancer Research UK 
 
  13 
Despite, those recommendations, >50% of all Swedish men aged 55-69 year have undergone 
a PSA test (45). However, PCT takes place even if it is not recommended. This is done based 
on the recommendation of individual physicians or by request of the patients. Godtman et al. 
(46) showed that organized PSA screening seems more effective than opportunistic 
screening. Compared to men offered an organized biennial screening program, unorganized 
screening resulted in more overdiagnosis. 
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The European Randomized Study of Screening for Prostate Cancer (ERSPC), in which 
Sweden participates, is a multicenter, randomized trial of screening for PCa of 162.388 men. 
About 900 PCa deaths have so far been recorded (47). The control arm consists of the usual 
care with no screening and the intervention arm is based on PSA testing every 2-4 years. The 
latest update showed that the absolute risk reduction of death from PCa at 13 years was 1.28 
per 1000 randomized men (47), thus confirming that PSA testing can lead to a considerable 
reduction in PCa mortality. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer 
Screening Trial is a large randomized trial designed and sponsored by the National Cancer 
Institute (NCI) in the US. One of the objectives was to determine whether screening men with 
DRE and PSA can reduce mortality from PCa by randomizing men to an intervention arm or 
a control arm (48). The PLCO trial indicated no reduction in PCa mortality. (49) But after 
accounting for differences in implementation and settings, it was shown that the ERSPC and 
PLCO provided compatible evidence that screening reduces PCa mortality (50). The ProtecT 
trial, a UK-based trial, aims at investigating the effectiveness of treatments for localized PCa 
by randomly assigning men to active monitoring, radiotherapy, or surgery (51). The ProtecT 
trial showed that active monitoring is as effective as surgery and radiotherapy in terms of 
survival at 10 years (37). The CAP (Comparison Arm for ProtecT) Randomized Clinical 
Trial comparing men aged 50 to 69 years undergoing one single PSA screening vs controls 
not undergoing this procedure, found that a single PSA screening intervention detected more 
low-risk PCa cases but had no significant effect on mortality after a median follow-up of 10 
years (52).  
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The controversies concerning prostate cancer screening highlights a consensus that informed 
decision making is of utmost importance when a man is to decide upon participation in 
prostate cancer screening. In 2017, a systematic review summarized men’s attitudes and 
perspectives of PCa screening (53) and presented the following figure:  
 
 Figure 4. Thematic schema of conceptual links among themes on men’s perspectives on 
prostate cancer screening 
 
Credit: James et al. Men's perspectives of prostate cancer screening: A systematic review of qualitative 
studies. PLoS One. 2017;12(11):e0188258. Published Nov 2017. doi:10.1371/journal.pone.0188258 
 
The review concluded that men are interested in participating in prostate cancer screening in 
order to prevent cancer and gain reassurance about their health. Fears of losing their 
masculinity, acceptance of the intrusiveness of screening and the ambiguities about the 
necessity were some of the obstacles that needed to be overcome for them to go ahead and 
proceed with PCa screening.  
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A qualitative study by Rai et al. also investigated influences on men’s decision to have a PSA 
test (54). The results suggest that the patient’s mind is already made up by the time he sees 
his GP, thus emphasizing the importance for the information about the pros and cons of PSA 
testing to reach men before visiting their GP:  
 
“Men wanted to be tested primarily because they believed in the benefits of 
early diagnosis. Triggers for consulting the GP were the personal experiences 
of friends with prostate cancer, a desire to be proactive about health, media 
reports, a family history or ongoing urinary symptoms. Before consulting the 
GP, men's awareness was largely based on personal accounts and media 
stories and did not include much familiarity with the potential limitations of 
testing. Many had decided they wanted to be tested by the time they consulted 
their GP and this decision remained largely unaffected by the consultation. 
Men varied in the value they placed on receiving information about the benefits 
and limitations of PSA testing from their GP.” (54) 
 
Men undergoing PSA testing did not show any significant increase in anxiety, even with an 
abnormal PSA result in one study (55). However, those with a disposition to anxiety 
experienced higher levels of anxiety than others throughout the screening process (55). A 
prospective questionnaire nested within the UK based ProtecT study confirmed that men 
receiving an abnormal PSA result did not experience increased anxiety and depression levels 
(56). However, men with a benign biopsy have been shown to be concerned about PCa (57, 
58). The Gothenburg section of the ERSPC reported anxiety associated with PCa screening to 
be low to moderate, even in men with elevated PSA (59). Anxiety affected a smaller group of 
men only. Anxiety when awaiting PSA results were only influenced (increased) if they had 
previously had elevated PSA tests. (59) 
 
In the Rotterdam section of the ERSPC trial, PCa screening participants did not experience 
considerable short-term impact on health related quality of life (HRQoL), despite short-
lasting side effects related to prostate biopsy (55) The results from the Finnish arm of the 
ERSPC supported that finding by concluding that short-term HRQoL effects of PCa 
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screening were minor and transient (60). Finally, a systematic review from 2011 concluded 
that screening does not appear to have long-term negative emotional impacts (61).  
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Several studies have suggested public acceptance for population-based risk-stratified cancer 
screenings (62-64). However, changing today’s cancer screening regimens to individualized 
screening based on risk will highlight the importance of educating potential screening 
recipients. Potential recipients will need to understand and be educated around the subtleties 
of risk:   
“Recipients or potential recipients of screening become responsible for developing an 
appropriate sense of their risk status and therefore eligibility for screening. Lower-risk 
groups acquire responsibility for developing a sense of proportion around their 
expectations, whilst higher-risk groups are required to be more vigilant” (65).  
 
The ProtecT feasibility study demonstrated that when using age-base thresholds of PSA 
levels to indicate abnormality, approximately 10% of men aged 50-70 years will have a 
raised PSA level, and about 70% of those will be false-positives (66). The PLCO cancer 
screening trial showed that trial adherence was poorer among those who had received 
previous false-positive results (67). This emphasizes the importance of personalizing PCa 
screening by risk-stratification to increase avoidance of false-positives.   
 
$%/%#  (&-+)+)
During the last decade, additional tests that could complete the picture given by a PSA test 
have been developed. The added tests are aiming at reducing the number of men needing to 
undergo biopsy and thus decreasing overdiagnosis.  
 
One method being tested is multi-parametric magnetic resonance imaging (MP-MRI). MP-
MRI can be used to triage men with high-serum PSA to avoid unnecessary TRUS-biopsy, 
and therefore avoid side-effects from the biopsy. According to Ahmed et al (68) mpMRI, 
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when used before prostate biopsy to triage the men, could reduce unnecessary biopsies by a 
quarter.  
Siddiqui et al. (69) studied targeted prostate biopsies, that is biopsies using a fusion of MRI 
and ultrasound, and found that they could increase the detection of high-risk PCa.  
New molecular biomarkers that classify tumor aggressiveness have also become available. 
By using biopsy tissue, different gene assays can tell more about the patients’ prognosis (70-
72). 
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The purpose of the Stockholm 3 (STHLM3) project was to develop and validate a risk-based 
PCa testing model (the STHLM3 model) in order to identify high-risk PCa (with a Gleason 
score of at least 7) with better test characteristics than that provided by PSA testing alone. 
The primary aim was to increase the specificity compared with PSA alone without decreasing 
the sensitivity to diagnose high-risk PCa (2). In other words, decrease the number of 
unnecessary prostate biopsies and reduce overdiagnosis without compromising the ability to 
diagnose high-risk PCa compared to PSA alone.  
 
$%0%$ 1'
The STHLM3-model consists of a combination of plasma protein biomarkers, genetic 
markers, clinical variables, and a prostate exam. In addition to total PSA, the other plasma 
protein biomarkers were selected based on a systematic scientific literature search as well as 
two subsequent validation studies using the STHLM2 cohort. On that basis, free PSA, hK2, 
intact PSA, beta-microseminoprotein (MSMB) and macrophage inhibitory cytokine-1 (MIC-
1) were selected due to their (substantial) correlations with the presence of Gleason Score ≥ 7. 
Moreover, based on literature search and genetic assessment in several studies, 254 single 
nucleotide proteins (SNPs) were selected based on their association with PCa (73-75). 
Finally, clinical variables (age, family history, previous prostate biopsy), and a prostate exam 
(digital rectal exam and prostate volume) were selected based on their association with PCa 
risk.  
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STHLM3 was a prospective, population-based diagnostic study of men without PCa aged 50-
69 years from Stockholm, Sweden. The study followed a paired screen positive design, where 
two tests (PSA alone and STHLM3 model) were performed on each study participant. The 
men were randomly invited by date of birth from the Swedish Population Registry kept by 
the Swedish Tax Agency. Men with PCa at enrollment were excluded from the study. The 
invitation included: 
1. An invitation letter with brief information about the study 
2. A study information brochure with comprehensive information about the study and 
reference to the STHLM3 website (www.sthlm3.se) for additional information 
3. A combined referral and consent form with three questions on family history, one 
question on previous prostate biopsy and one question about current use of certain 
medication 
4. A list of 67 laboratories in Stockholm participating in STHLM3. 
 
Those who chose to participate in STHLM3 were also invited to respond to a more extensive 
web-survey. The survey covered demographics, medical history, bladder specific questions, 
use of alcohol and tobacco, diet, physical activity, and use of selected drugs. A subset of the 
men was also asked to respond to psycho-social questions within the Stockholm 3 Quality of 
Life (“S3QOL”) study. Data from this subset of questionnaires form the basis of two of the 
papers in this thesis (paper III and IV). 
 
PSA levels were analyzed in all participants. Men with a PSA concentration of less than 1 
ng/mL were excluded from being tested with the additional biomarkers from the STHLM3 
model. Men with a PSA of at least 3ng/mL or the STHLM3-model result indicating high risk 
were considered to be at an increased risk of PCa and were referred to a urologist (see Figure 
5).  
 
Each participant received a response letter by mail based on the results of the PSA test or 
STHLM3 model. The letter provided one of the following three recommendations: (1) “Low 
risk” with the recommendation to perform a new test in six years; (2) “Normal risk” with the 
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There has been a push towards individualized PCa screening as a means to reduce the harms 
of PCa screening. Before implementing a new screening method, like here a risk-based PCa 
screening, it is important to assess whether the general population is interested in knowing 
their risk and using that new method for individualized screening intervals. It is also 
important to examine if and how that new method affects those invited. Better understanding 
of men’s views on participation in individualized prostate cancer testing (PCT) will help 
inform the development of population-based screening programs. The overarching aim is to 
increase knowledge concerning men’s views on participation in individualized PCT to help 
policy-makers in their decision to implement public prostate cancer screening.   
 
The center of our focus lies in individualized PCT. “Individualized” is used interchangeably 
throughout the thesis with personalized, risk-based, and risk-stratified. The emphasis is 
specifically upon men’s views on participation to PCT. 
 
The specific aims of the studies are as follows: 
 
Study I: To explore the interest in and acceptability of the prospect of individualized prostate 
cancer testing and mammography screening. 
 
Study II: To examine factors in the invitation to PCT (pre notification, invitation letter, and 
reminder) to optimize participation in PCT. 
 
Study III: To examine, three months before invitation to participation in PCT, factors of 
importance for participation in PCT (PCa worry, knowledge of PCa, attitudes towards PCT 
and health related quality of life (HRQoL)). 
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Study IV: To investigate if there were differences between the risk groups five months after 
participation in PCT in terms of worry, knowledge, attitudes and HRQoL, and to examine 
changes over time in these variables.
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Through our four studies we have looked at three different time aspects surrounding PCT.   
The first time point consisted of taking a picture of a moment in time. The aim was to 
describe individuals’ interest in or attitudes towards individualized cancer screening in a large 
sample of the population. Thus, Paper I is a cross-sectional study that measures men’s’ and 
women’s’ opinion and views to the prospect of risk-stratified screening for PCa and 
mammography, respectively. The study was conducted a few years before individualized 
PCT was carried out through STHLM3.  
The second time aspect represents the papers leading up to PCT, i.e. upstream of PCT. Their 
goals were to give a picture of various predictors for participation in PCT. In Paper II, 
factors that affect men’s participation from a methodological aspect were investigated. This is 
an experimental prospective study where the investigator intervenes in multiple ways to 
affect the outcome. Paper III is an observational prospective longitudinal study designed to 
examine psycho-social predictors of PCT, carried out three months before the invitation to 
participate in STHLM3.  
Finally, the third time aspect in this thesis is reported in Paper IV in which the downstream 
effects of PCT participation on men are examined prospectively from before invitation to five 
months after participation in STHLM3. 
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“SARA” stands for “Survey About Risk Assessment”. A total of 10.000 individuals between 
20 and 74 years of age were randomly selected from the Swedish population, collected from 
the SPAR registry. They were selected to match the age and sex distribution of the Swedish 
population as registered in 2009. The participants were contacted via a mailed letter and 
asked to login to a web-survey. The women were asked about their opinions concerning the 
prospect of individualized mammography whereas the men were asked about individualized 
PCa screening. The invitation letter’s heading introduced the subject by asking the following 
question: “Would you like to influence future mammography/prostate cancer screening?”. 
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The letter then went on to elaborate the concept of risk-stratified screening and subsequent 
individualized screening program. The letters were mailed in November 2011 and data was 
collected until January 2012. Within this thesis, the emphasis will be upon the results of 
men’s interest in individualized prostate cancer testing. However, for the sake of comparison, 
the men’s results will be discussed against the women’s results, and their views on the 
prospect of individualized mammography screening.  
 
A sub-sample of 300 persons who did not participate in the survey was randomly selected for 
telephone interviews in order to study reasons for non-participation. Respondents were asked 
two questions: their reason(s) for not participating and if they would want to know their 
breast/prostate cancer risk.  
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The study sample examined in Paper II was embedded in the pilot study for STHLM3 and 
was conducted to test for optimal survey design and procedures for data collection in order 
to achieve maximum participation to PCT through the STHLM3-trial. In the fall of 2012, 
during six consecutive weeks, invitations were mailed out to a total of 28.134 men, 50-69 
years of age, living in the region of Stockholm, without previous prostate cancer diagnosis. 
The men were randomly selected by date of birth from the Swedish Population Registry in 
a quasi-randomized fashion and allocated to receive: (a) a pre-notification postcard or not; 
(b) a shorter or a longer invitation letter; (c) a shorter or a longer web-based questionnaire; 
and (d) a reminder or not. The allocation patterns were combined into six study arms. Men 
who chose to join the STHLM3 were also invited to respond to a more extensive web-based 
questionnaire. The questionnaire covered demographics, bladder specific questions, 
medical history, use of selected medicines, use of alcohol and tobacco, diet, and physical 
activity. For the purpose of this thesis, we will focus on the impact the different 
methodological survey designs had on participation in PCT, but not on participation in the 
STHLM3 questionnaire. Studying how to increase participation to epidemiological 
questionnaires is an interesting and important aspect of research, but is not the focus of this 
thesis.  
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S3QOL stands for “STHLM3 Quality of Life” and is a study sample that was nested in the 
STHLM3-trial. The study sample for S3QOL consists of a sub-sample of 10.000 men of the 
invited STHLM3 study population. Psycho-social aspects were studied at three time-points 
surrounding STHLM3: (1) Three months before being invited to STHLM3, (2) alongside 
participation to STHLM3 and, (3) five months after participation to STHLM3. In January 
2014, 10.000 men who were due to be invited to participate in STHLM3 three months later, 
received an invitation to complete a web-survey. The web-survey covered four main psycho-
social areas: (A) PCa-specific worry and perceived vulnerability; (B) Knowledge about PCa; 
(C) Attitudes and health behavior towards PCT; and (D) Health-related quality of life 
(HRQoL). That same web-survey was inserted in the STHLM3 questionnaire for the men to 
complete if/when they participated in STHLM3. Finally, in September 2014, an invitation 
was sent asking the men to fill out the same web-survey. The S3QOL study sample is 
described in Paper III and IV. 
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The questionnaire used in Paper I was developed by a panel of clinical, psychological, and 
epidemiological experts. Pilot interviews with 20 healthy women and 10 healthy men were 
conducted according to the EORTC guidelines for questionnaire development (76). This was 
done to ensure the cultural and linguistic integrity of the questions. A pilot study was carried 
out on a random sample of 200 women from the Swedish population in order to test the 
web’s functionality and the study logistics. The final questionnaire consisted of two parts: (A) 
Public interest in cancer risk and underlying reasons (3 items), and (B) Public acceptability of 
the prospect of risk-based screening (7 items). The response alternatives were given on a 
four-point Likert scale and ranged from Absolutely/Agree to Definitely not/Disagree. For 
some items the option ‘Neither’ was added. The original questionnaire was developed in 
English and translated into Swedish by a professional translation agency. An English version 
of the questionnaire can be found in the Supplementary content of Paper I. 
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The outcomes measured in Paper II were the proportion of completed web-based 
questionnaires, the proportion of men who performed PCT by providing blood within 
STHLM3, and the proportion of participants who completed both. The focus in the thesis 
remains on the relationships between the four different survey design aspects studied in the 
pilot study (pre-notification, length of invitation letter, length of questionnaire, and reminder) 
and the proportion of men who actually participated in PCT.  
 
The pre-notification consisted of a postcard describing the upcoming invitation to participate 
in STHLM3 and was sent one week ahead of time. The information provided in the 
invitational package consisted of an invitation letter with, at the back of it, a checklist 
explaining the procedure for giving blood in the PCa testing, as well as an extensive brochure 
with in-depth information about STHLM3. The difference between the short and long 
invitation letter consisted in the number of words on the first page of the letter. The long 
version was twice as long as the short one. An English version of the letters can be found in 
the Supplementary material of Paper II.  
 
Those who belonged to an intervention arm where a reminder was included were sent one 
two weeks after receiving the invitation letter, regardless of whether they had already 
participated or not. 
Men who choose to participate in STHLM3 were also invited to respond to a more extensive 
web-based questionnaire. The questionnaire was not a mandatory aspect of PCT. Its sole 
purpose was to collect data for different research projects in relation to STHLM3. In the pilot-
study, two versions of the questionnaire were tested. A short one consisting of 500 items and 
a long one consisting of 1000 items.  
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S3QOL consisted of questionnaires covering six different areas. Four of those were used in 
Papers III and IV: Worry, Knowledge, Attitudes and health behavior, and HRQoL. The 
items used in our questionnaires have been used in previous international PCa studies. They 
were translated into Swedish by a certified translator. 
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5.3.3.1 Prostate cancer specific worry and perceived vulnerability 
The worry-questionnaire consisted of six items adapted from items used previously in 
different studies (58, 77, 78). The items and response options can be found in Paper III.  
 
5.3.3.2 Knowledge about prostate cancer 
The six-item questionnaire used in S3QOL to measure PCa knowledge was previously 
developed and used by McNaughton-Collins (79) for men without a prostate cancer history. 
The items and response options can be found in Paper III.  
5.3.3.3 Attitudes and health behavior 
A questionnaire was developed for a study with the aim to identify predictors of attendance 
for PCT and prostate biopsy (Avery et al., 2012). The questionnaire consists of 26 items 
comprising six domains: (A) Perceived threat of developing prostate cancer (2 items), (B) 
Perceived benefits of PCT (8 items), (C) Perceived barriers to PCT (10 items), (D) Intentions 
to undergo PCT (1 item), (E) External influences on PCT decision making (3 items), and (F) 
General health (2 items). 
5.3.3.4 Health-related quality of life 
To measure HRQoL The EORTC Quality of Life Core Questionnaire (QLQ-C30) version 3 
was used. This is a cancer-specific questionnaire consisting of 30 items. It incorporates five 
functional scales (physical-, role-, cognitive-, emotional- and social functioning), three 
symptom scales (fatigue, pain, and nausea/vomiting), and a global health and quality of life 
scale. For the latter scale, responses range from 1 (“Very poor) to 7 (“Excellent”), whereas 
the response options for the other scales are scored with 4-point scales ranging from 1 (“Not 
at all”) to 4 (“Very much”). The EORTC QLQ-C30 has been widely used in cancer-related 
settings since the 1990’s when it was first developed (80). The Swedish version of the older 
core instrument (EORTC QLQ-c36) has shown overall validity (81) and there is reference 
data from the Swedish population (82).  
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In Paper I, in order to test for possible differences between respondents and non-respondents, 
a Kolmogorov-Smirnov test was conducted on the age distribution and a chi-square test on 
the sex-distribution. To test for differences according to sex, age-group and education, Chi-
square tests were performed.  
 
For Paper II, participation rates between the different arms were compared by performing 
Chi-square tests with a significance level set to 0.05.  
 
In Paper III, ordinal categorical data (such as found in the worry and knowledge 
questionnaires) were analyzed using Fisher’s exact test. For analysis consisting of comparing 
population means (as in the Attitude and HRQoL questionnaires), independent Student t-tests 
were performed. The level of significance was set to 0.05. 
For the “Attitudes and health behavior” questionnaire, we added the possibility for 
participants to respond ‘Do not know’. Items in each scale were summed only if half or more 
of the responses in the scale were not composed of the response item “Do not know”. 
Summary scores were produced for each scale.  
For the EORTC QLQ-C30 questionnaire, all scales were linearly transformed ranging from 0 
to 100. The nausea and vomiting symptom scale as well as the single-items, with the 
exception of “Pain”, are not reported in this paper as we did not consider them pertinent to 
this study.  
 
For paper IV, the response options for the Worry and Knowledge questionnaires were 
dichotomized. Wilcoxon signed rank tests were used to test for evidence of association 
between baseline and follow-up within a risk-group. Analysis of Covariance (ANCOVA) 
were used to compare between the four risk-groups (while controlling for baseline) in a 
pairwise manner.  
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Missing data can refer to either missing items or missing questionnaires (or part of 
questionnaires). Missing data can be dealt with differently depending on the situation.  Due to 
technical error during the collection of data, 63 men were not given the opportunity to 
respond to the worry questionnaire at baseline in S3QOL and the subscales (A) and (B) in the 
Attitudes and health behavior questionnaire were incomplete at follow-up. In Paper III and 
IV, those missing men in the worry questionnaire were removed from the analysis and in 
paper IV, the analysis of the subscales (A) and (B) of the Attitudes and health behavior 
questionnaire had to be omitted altogether. 
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All studies included in the thesis have received ethical approval, including amendments, from 
the Regional Ethical Review Board in Stockholm. The SARA study was approved in 2011 
(ref 2011/630-31/4). The STHLM3 study was approved in 2012 (ref 2012/572-31/1). The 
S3QOL study was conducted following an addition to the application for STHLM3. This 
addition was approved May 27th 2013.  
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Population based selection of individuals for invitation to respond to questionnaires includes 
the risk that recipients who are affected by cancer may be affected by worry as they are 
reminded of cancer and maybe screening/testing. They may also suspect that they have been 
selected based on their cancer experience. None of those invited has, however, contacted us 
concerning this problem.  
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Data for this paper was collected during the STHLM3-pilot study. This particular paper is a 
methodological paper that investigated the relative influence of different survey design 
factors on ensuing participation in STHLM3 trial. The reason those survey design aspects 
were evaluated was because concerns were raised over the optimal mailing procedures, 
including the use of pre-notification, length of invitation letters and questionnaires for the 
main study. Participants did not know that these survey design factors were the subject of a 
randomised controlled trial. Being allocated to different survey design arms is not research 
that involves sensitive information or biological material, and thus by law does not require 
ethical approval (83). The ethical application for STHLM3 pertains to the sensitive 
information and collection of biological material conveyed in the STHLM3 questionnaire and 
the blood provided within the frame of STHLM3. However, this study was important from an 
ethical aspect in the sense that STHLM3 and its ensuing PCT were going to involve a large 
sample of the population. Ergo, there was an ethical impetus to optimize participation. The 
results of Paper II were used in the STHLM3 trial, resulting in improvement of the 
participation rate. 
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An ethical aspect that needs to be discussed is the invitation at the first time point. When 
invited in January 2014, the men did not know about the impeding invitation to STHLM3 in 
April of the same year. In other words, they did not know of the longitudinal aspect of the 
S3QOL study. One could argue that it is not ethical to keep information from participants. 
But in weighing the pros versus the cons, we reasoned that achieving a “true” baseline 
measurement, i.e. not contaminated by the knowledge of the upcoming PCT/STHLM3, 
weighed heavier than disclosing how/why they had been chosen. Having that knowledge 
could have undermined the longitudinal study as a whole. Moreover, telling them about the 
upcoming PCT could have influenced their participation in the sense that they could have felt 
coerced to participate at the first time point in order to get to participate to STHLM3 later on, 
which was not the case. It would also probably have affected the results, as we were 
interested in investigating factors for participation outside the prospect of invitation to testing. 
The men could choose to ignore to participate or withdraw from the study at any point. 
Finally, although belonging to the S3QOL study sample meant being invited to respond to a 
questionnaire at three time points in a year, we lowered the eventual information burden or 
saturation the participants might feel by not sending reminders. 
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• Study I: Of the 10.000 individuals invited, 5049 were men. Among those, 1384 men 
(27%) responded to our web-survey. Among the non-respondents, 75% said in the 
interview that they wanted to know their risk. Respondents and non-respondents were 
not significantly different in age and sex. The most common reason for non-
participation stated in the interviews was ‘lack of time’. 
• Study II: Out of the 28.134 men included in Study II, a total of 9.543 men (34%) 
participated to STHLM3. Among them, 7.302 men provided blood for PCT and 
responded to the STHLM3 questionnaire; and 1.744 men only did PCT,  
• Study III: Out of the 10.000 men invited to S3QOL, 1.980 men (20%) responded to 
the S3QOL survey three months before invitation to STHLM3. Among them, 70% 
participated in the ensuing PCT within STHLM3, and 30% did not participate in 
STHLM3.  
• Study IV: Among the 10.000 men invited to S3QOL, a total of 994 men performed 
PCT and responded to the S3QOL survey at baseline and follow-up and were thus 
included in the analyses. Among them, 421 men were identified as ‘Low risk’, 421 
men as ‘Intermediate risk’ and 152 men as ‘High risk’ (93 men with a benign biopsy 
result and 59 men with a confirmed PCa diagnosis). 
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The level of interest to individualized PCT and acceptability of risk-stratified PCa screening 
was assessed in Paper I. A vast majority of the men (95%) stated wanting to know their PCa 
risk with 73% responding “Absolutely” and 22% “Maybe”. The major reasons for wanting to 
know one’s risk were to avoid worrying (89%), to get a realistic view of the future (83%) and 
to get rid of uncertainty (78%).  
A total of 69% stated that they would like to participate in an organized prostate cancer 
screening. If identified with a high risk, they stated that they would agree to undergo 
screening more often than average. When asked “If identified as having a low risk, would 
you agree to undergo screening less often than average?”, a majority of the men were still 
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positively inclined in doing so, but the level of certainty dropped. Older age predicted being 
more certain, whereas higher education was associated with less certainty.  
Moreover, in order to assess their PCa risk, 62% of the men responded being comfortable in 
conveying personal information and 71% comfortable in conveying genetic information. 
Finally, the preferred mode of communication of the risk was via consultation with a GP but 
almost 60% of the men were accepting communication via mail.   
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Through Paper II and III we researched factors upstream of PCT that could increase or 
predict ensuing PCT uptake.  
 
Paper II investigated methodological aspects that might affect subsequent participation to 
PCT and revealed that use of a pre-notification increased PCT uptake, both among men who 
only provided blood for PCT (p=0.002) and among men who provided blood for PCT and 
completed the STHLM3 questionnaire (p=0.0007).  
 
Paper III investigated psycho-social factors in relation to PCT participation by comparing 
baseline measurements before invitation of men who subsequently declined participation to 
PCT to men who participated. The following results were found: 
- A higher proportion of participants reported worry to some degree (p=0.02) 
- A tendency among participants to perceive their risk of getting PCa as slighlty higher 
than decliners (p≤0.05) 
- A tendency among participants to consider their likelihood of developing PCa in the 
next five years as slightly higher than decliners (p=0.003) 
- Levels of knowledge were low in both groups since less than 50% responded 
correctly to five of the six knowledge items. However, Decliners responded “Do not 
know” more often. 
- Participants indicated greater benefits of prostate testing (p=0.0005), less barriers to 
PCT (p<0.0001) and a higher desire for better general health (p=0.03) 
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- Participants presented a better global health status (p<0.0001) 
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In Paper IV, the men’s psycho-social factors downstream of PCT were compared at follow-
up to their answers at baseline to investigate possible effects of PCT participation over time. 
When compared to baseline, Low-risk individuals and Intermediate-risk individuals reported 
reduced worry levels at follow-up. Additionally, high-risk individuals did not report increased 
worry levels at follow-up. High-risk individuals, who had had a negative biopsy, reported a 
reduction in their perceived likelihood of developing cancer in the next five years, whereas 
high-risk individuals who had been diagnosed with PCa reported an increase in PCa worry 
affecting their daily life.  
A vast majority of the respondents answered incorrectly at the questionnaire on PCa 
knowledge, whether at baseline or at follow-up, reflecting a low level of knowledge across 
the groups. Group comparisons between the different risk-levels suggested that high-risk men 
had learned more over time than low-risk and intermediate-risk men. 
Both the Low risk group and the Intermediate risk group scored statistically significantly
lower on “External influences” and “General Health” at follow-up compared to baseline. In 
the High-risk group and in the PCa diagnosis group, “Barriers” increased over time. The 
High-risk group and the PCa diagnosis group scored statistically significantly higher on 
“Barriers to screening” than the Low risk group. This difference (p<0.001) was also 
foundwhen comparing the Intermediate risk group to the High-risk group and the PCa 
diagnosis group. 
 No statistically significant changes between baseline and follow-up were found for 
HRQoLin any of the groups, with one exception. Emotional functioning improved over 
time in the Intermediate-risk group. 
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There are still many aspects that need studying before PCa joins the rank of screening 
programs offered to the general public. However, this thesis and the paper it encompasses, 
sheds light on men’s interest and acceptability towards a risk-based PCa screening program. 
and adds knowledge concerning psychosocial characteristics surrounding individualized 
PCT.  
 
One of the criteria for a screening program to be adopted is that “The test should be 
acceptable to the population”(41). Although hampered by a low-response rate, the results of 
Paper I suggests that there is a public interest in and acceptability of establishing risk-
stratified screening programs. This goes along the line of previous studies that found a similar 
high interest in genetic testing and personalized screening (84-86). There seems to be, 
however, a discordance between claimed interest and actual uptake. A total of 73% of the 
men who responded to Study I stated that they would like to know their PCa risk, whereas 
approximately 40% of the STHLM3 study sample ended up participating and performing a 
risk-based PCT. For example, the European Guidelines for Quality Assurance in Breast 
Cancer Screening recommend an uptake of at least 70%. However, only half of 26 European 
breast cancer screening programs achieve that percentage (87). Some of the reasons stated for 
not attending a routine breast screening are “feeling embarrassed”, “having a lack of breast 
cancer symptoms”, and “forgetting to go to the appointment” (88). A colorectal cancer 
screening study found that personalized cancer risk information could either increase or 
decrease an individual’s interest in colorectal cancer screening, depending on prior screening 
history, estimated cancer risk and baseline screening interest (89).  
 
Although there is an interest to participate in prostate cancer testing and an acceptability for 
an individualized screening program, there seems to be, however, more hesitancy for being 
screened less often if identified as having a low risk of PCa than for being screened more 
often if identified with a high risk. More research is needed to see whether men would accept 
the recommendation of not needing to be screened again if having a low risk. More research 
is also needed to see if that hesitancy would affect PCT uptake. 
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The results presented in this thesis increase our knowledge around factors that affect men’s 
participation in risk-based PCT. As presented in Paper II, the use of a pre-notification card 
increased participation to the web-survey, but more importantly, it also increased 
participation in PCT. Moreover, as discussed in Paper III, when PCT participants were 
compared to PCT decliners, 70% of our respondents ended up participating in the ensuing 
PCT (compared to the 40% observed in STHLM3). This could be due to selection bias, but 
we cannot rule out that the baseline questionnaire in itself triggered an interest in PCT (a little 
bit like a pre-notification) and increased participation to PCT. Thus, responding to the 
questionnaire might have reinforced PCT participation. However, more research is needed to 
understand what aspect of the pre-notification and possibly questionnaire might affect PCT 
uptake. 
 
As shown previously in several studies, men undergoing PSA testing do not show any 
significant increase in anxiety, even with an abnormal PSA result (55, 56, 59). Similarly, 
Paper IV, did not observe higher worry levels among men with an abnormal PSA result. 
Interestingly, Paper IV showed a decrease in worry level among men with normal PSA 
results. These results reinforce and justify the notion that the mental harm of PCa screening is 
not source of major concern.  
 
When deciding upon whether to offer PCT or not to the general population, The Board of 
Health and Welfare (Socialstyrelsen) investigates, among other, whether the test method is 
accepted by the population (90). It has been shown that men who find out that they have a 
“normal” PSA-test find that reassuring (91). Our results in Paper IV showed that men who 
find out that they have a low or intermediate risk of developing PCa reported decreased worry 
levels. Moreover, “integrate education” and “ensure informed choice” are two screening 
criteria that need to be met for a screening to be adopted. The results in Paper IV shed light 
on the need for more education around PCT.  
 
The present findings concerning PCT participation and its lack of effect on HRQoL concur 
with those of other international studies (55, 60, 61) . Similarly to Hewitson et al. (92) who 
claimed that it was only with the development of a breast cancer screeningspecific 
instrument (the Psychological Consequences Questionnaire (93)) that subtle measures of 
cognitive and emotional responses to screening could finally be detected. (92), Brindle et al. 
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suggests that the used instruments may not adequately measure the psychological impact 
associated with PCT participation, explaining the failure to detect possible psychological 
effects of screening (56). 
 
Because the response rates in our surveys were low, we are faced with the risk that 
respondents differ systematically from non-respondents. Indeed, the participants in our study 
probably had an initial interest in the subject to want to log-in and respond to our web-
surveys. This creates a participation bias (or non-response bias). It is a phenomenon in which 
the results become non-representative because the participants are systematically different 
from the target population, and may bias the results. Epidemiological and psychological 
research often involves questionnaires or web-surveys, and it has become more and more 
difficult to achieve high response rates when studying the general population. (94, 95). 
However, although not perfect, our non-respondent analysis for Paper I showed that a 
majority of the non-respondents stated wanting to know their cancer risk and that lack of time 
had been a common reason behind not answering.  
 
For a screening program to be worthwhile, the uptake within the concerned population needs 
to be high. Our results are giving indications as to which men would seek PCT and which 
men would decline PCT in terms of psycho-social factors. This information will help inform 
health policy makers in order to increase participation in risk-based PCT. In line with other 
studies that showed that PCa knowledge is a predictor of participation in PCa screening, our 
results reinforce the need for more education in relation to PCT (96, 97). Especially since the 
decision to undergo PCT, whether PSA-based or risk-based, relies largely on an educated and 
informed decision.
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The results presented in this thesis add to the body of evidence regarding participation in 
individualized prostate cancer testing from a psycho-social standpoint. There is an interest to 
participate in prostate cancer testing, and there is an acceptability for an individualized 
screening program. There seems to be, however, more hesitancy behind the idea of being 
screened less often if identified as having a low risk of PCa than behind the idea of being 
screened more often if identified with a high risk. However, according to Paper IV, from a 
worry perspective, the men who were recommended to be screened less often, were the ones 
who gained the most from performing PCT since their worry levels decreased after 
performing risk-based PCT. More importantly, being identified as having a high risk for PCa 
did not induce heightened worry levels over time.  
 
Men identified as having a high risk perceived more barriers concerning PCT at follow-up. 
Moreover, men identified as having a low or intermediate risk reported being less affected at 
follow-up by external influences and by aspects concerning health. Finally, only two 
differences were observed in terms of HRQoL. Men with intermediate risk reported increased 
emotional functioning over time and, surprisingly, men who were diagnosed with PCa 
presented a tendency to lower levels of pain over time, especially when compared to the low 
risk group.  Otherwise, no differences were observed in terms of change of quality of life by 
undergoing PCT.  
 
When compared to men who declined participation to PCT, men who participated in PCT 
reported slightly more worry as well as a heightened perceived vulnerability to PCa. 
Moreover, PCT participants perceived more benefits and less barriers from PCT participation 
than PCT decliners. Additionally, PCT decliners reported a lower global health status, lower 
emotional functioning and higher levels of fatigue compared to PCT participants.  
 
As for PCa knowledge, no differences were observed between PCT participants and PCT 
decliners. The level of knowledge was low overall. Interestingly, where participants and 
decliners differed was in the certitude of the knowledge, i.e. decliners more often responded 
“Do not know”. More research is needed to understand how this knowledge (or lack thereof) 
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affects PCT uptake. Our results suggest that undergoing PCT did not increase their level of 
knowledge over time, unless identified as having a high risk. Information about PCa and the 
pros and cons with PCa-testing have to be improved in the public in order for men to take an 
informed consent to participate. 
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Prostatacancer (PCa) är den vanligaste cancerformen hos män i Sverige och utgör en 
tredjedel av cancer hos män. År 2016 fick 10 474 män diagnosen PCa. Socialstyrelsen 
rekommenderar inte screening för PCa med enbart prostataspecifikt antigen (PSA-prov) (43). 
Nackdelen med screening med enbart PSA-prov är att många män diagnosticeras med PCa 
trots att sjukdomen aldrig riskerar att utvecklas till en allvarlig sjukdom. Detta innebär att 
många män utsätts för biopsi och ev. komplikationer i onödan, samt får leva med en PCa 
diagnos och de psykosociala konsekvenser som medföljer. Det anses därför att nyttan med 
PSA-screening inte överväger de negativa effekterna. 
 
Flera tester som kan komplettera PSA-provet har utvecklats under senare år vilket ger 
möjlighet att minska överdiagnostik och överbehandling. En metod som utvecklats är 
STHLM3-modellen. Utöver PSA ingår olika markörer samt genetisk information för att 
beräkna den individuella risken för PCa. STHLM3-modellen har visats vara bättre när det 
gäller att identifiera högrisk PCa och samtidigt minska behovet av biopsi. Baserat på en 
riskprofil (låg, normal eller hög) kan individanpassad screening erbjudas. I dagsläget finns 
det dock ej mycket kunskap kring hur en sådan individanpassad PCa test skulle påverka 
männens hälsorelaterade livskvalitet (HRQoL), deras attityder till deltagande i screening och 
PCa-testning (PCT), samt deras kunskaper om PCa. 
 
Det övergripande syftet med denna avhandling var att undersöka ovanstående aspekter av 
risk-baserad PCT. 
 
Artikel I: att utforska intresset för och acceptans i befolkningen av individanpassad PCT och 
mammografiscreening.  
 
Artikel II: att undersöka faktorer vid inbjudan till PCT såsom påannonsering, 
inbjudningsbrev, frågeformulär och påminnelse för att optimera deltagande i PCT.  
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Artikel III: att undersöka sambandet mellan deltagande i PCT och oro, kunskap, attityder 
kring PCT samt HRQoL tre månader före inbjudan till PCT.  
 
Artikel IV: att undersöka skillnader mellan de olika riskgrupperna (låg, normal, hög) fem 
månader efter PCT rörande oro, kunskap om PCa, attityder kring PCT och HRQoL, samt 
undersöka om dessa faktorer ändras över tid i de olika riskgrupperna. 
 
#@%$ 


Data för Artikel I, III och IV insamlades med frågeformulär. I Artikel II randomiserade 
männen till olika former av inbjudningsfaktorer till PCT. Frågeformulären som användes i 
Artikel I utvecklades av en expertpanel, med frågor om befolkningens intresse av att veta sin 
individuella cancerrisk samt i vilken utsträckning de skulle acceptera att delta i en risk-
baserat screeningprogram. Frågeformulären i Artikel III och IV utgörs av frågor som 
använts i tidigare forskningsstudier och består av fyra formulär som mäter männens oro, 
kunskap, attityder gentemot PCT samt HRQoL. 
 
I Artikel I inbjöds 10 000 personer mellan 20–74 år från Sveriges befolkning, med en 
svarsfrekvens på 28%. Svaren jämfördes mellan kvinnor och män, åldersgrupper samt 
utbildningsnivå.  
Artikel II baserades på STHLM3:s pilot-studie, vilken innefattade 28 134 män 
randomiserade till sex olika inbjudningsfaktorer (påannonsering eller ej, kort eller långt 
inbjudningsbrev, kort eller långt frågeformulär och påminnelse eller ej) för att undersöka 
dessa faktorers påverkan på deltagande i PCT. Cirka 34% av de inbjudna deltog i påföljande 
PCT. 
I Artikel III och IV inbjöds ett urval av 10 000 män som ingick i STHLM3-projektet till att 
svara på ett webbaserat frågeformulär vid tre tidpunkter: tre månader innan inbjudan till 
deltagande i STHLM3, i samband med deltagande i STHLM3 samt fem månader senare. 
Cirka 20% svarade vid den första tidpunkten medan cirka 10% svarade vid både det första 
och den sista tidpunkten. 
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Artikel I rapporterade att majoriteten av både män och kvinnor var mycket intresserade av att 
känna till sin individuella prostata- respektive bröstcancerrisk. Män verkade en aning mer 
övertygade än kvinnor, men viljan var hög hos båda kön. Majoriteten ville screenas oftare om 
de skulle ha hög risk för PCa, men färre var intresserade av att screenas mer sällan än 
genomsnittet om de hade låg risk för PCa.  
 
Artikel II visade att användandet av påannonsering samt påminnelse ökade deltagandet i 
PCT. Denna metod användes senare i inbjudningarna till STHLM3 och deltagandet ökade i 
jämförelse med pilotstudien där inbjudningsfaktorerna testades. 
 
Artikel III visade att de som deltog i PCT skattade mer oro kring PCa samt en högre känsla 
av sårbarhet än män som ej deltog i PCT. Dessutom hade de som avböjde deltagande i PCT 
en något lägre HRQoL. Båda grupperna visade låg kunskapsnivå gällande PCa överlag.  
 
Artikel IV rapporterade få skillnader gällande HRQoL över tid oavsett riskgrupp. Männen i 
högriskgruppen visade ingen ökning i oro över tid, men en minskning i orosnivån noterades 
över tid hos män som tillhörde låg- eller normalriskgrupperna. Även här noterades en låg 
kunskapsnivå gällande PCa överlag även om högriskgruppen visade en förbättring över tid.  
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Många människor är intresserade av att få information om sin individuella bröst- och 
protatacancerrisk, vilket är en förutsättning för riskbaserad screening. Inbjudningar till PCT 
kan optimeras genom påannonsering och påminnelse. Kunskaperna om PCa bland män i 
befolkningen är låg. Denna kunskapsnivå behöver förbättras för att män ska kunna fatta ett 
informerat beslut om de inbjuds att delta i PCT. Detta är viktigt om PCa screening skall 
införas. Att deltagande i PCa-screening leder till negativa psykosociala konsekvenser har 
varit ett av huvudargumenten för att inte införa screening. Föreliggande studie stöder inte 
detta antagande. Risk-baserad PCT tycktes inte ha någon negativ påverkan på männens 
välmående, oavsett riskgrupp 
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their busy life to participate in the different studies included in this thesis. Your contribution 
is deeply appreciated, so thank you! 
 
Throughout my years as a doctoral student, I have had the pleasure to meet many PhD 
students and unfortunately heard through them that having a supportive and understanding 
supervisor is not always a given. I have therefore come to cherish my main supervisor, 
Yvonne Brandberg, all the more. You have guided and cheered me throughout all my PhD 
years. I early on understood that you had my back when you “fought” for my salary at the 
beginning of my doctoral education. Sitting and discussing research was always a pleasure, 
but you went beyond that in my opinion when you encouraged me to take breaks and to 
remember to enjoy some time off too. You see the whole person in your colleagues and your 
students. I was so proud when you were one of the few professors to participate in student 
activities at the department. It shows your commitment. Thank you also for being a source of 
inspiration in your “fight” for feminism and equality within the Department!  
 
I am also grateful for having been surrounded by amazing female research figures. I still 
remember to this date sitting at a restaurant towards the beginning of my journey with 
Yvonne Brandberg and Mirjam Sprangers and thinking that I was so lucky to sit with two 
so successful women in the research field. I remember being in awe that night. Mirjam, I 
don’t know if you know it but you send out such calming vibes. I have cherished the times I 
have had a moment to sit and discuss with you and I have always looked forward to your 
comments on my drafts. I have learned so much in terms of writing thanks to your comments. 
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I had! You are such a delight to have discussions with and to converse about life and society. 
 
Big thank you to Raph Mouth too, whom I met while studying in Belgium. You are a breath 
of fresh air and your energy is incredible! I do not know how you find time to do it all! 
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wouldn’t be the same without having met you! Those were the best years of my life and you 
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without whom there is no party!  
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